This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Acute severe asthma in general practice

Authoring team

On assessment:

  • PEF 33–50% best or predicted
  • SpO2 ≥92%
  • cannot speak in completed sentences
  • has a pulse rate of ≥110 beats/min
  • respiratory rate ≥25 breaths/min

Management:

  • serious consideration for immediate admission if more than one feature of the above present.

Treatment:

  • give oxygen to maintain SpO2 94–98% if available
  • β2 bronchodilator:
    • nebuliser (preferably oxygen driven) (salbutamol 5 mg)
    • or via spacer (give 4 puffs initially and give a further 2 puffs every 2 minutes according to response up to maximum of 10 puffs)
  • oral prednisolone 40–50 mg or IV hydrocortisone 100 mg

Monitor response 15-30 minutes after nebuliser therapy.

If any signs of acute severe asthma persist then arrange hospital admission.

  • remain with patient until ambulance arrives
  • send written asssessment and referral details to hospital
  • β2 bronchodilator via oxygen-driven nebuliser in ambulance (1)

Follow-up:

  • monitoring of symptoms and PEF
  • give self management plan
  • review at GP surgery in <= 24 hours

At review, modify treatment according to guidelines for chronic persistent asthma.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.